Dr Reddy's announces commercial launch of COVID-19 drug 2-DG

Drug major Dr Reddy's Laboratories on Monday announced the commercial launch of COVID-19 treatment drug, 2-deoxy-D-glucose (2-DG), at a maximum retail price of Rs 990 per sachet.

The company will supply the drug to major government as well as private hospitals across India, Dr Reddy's said in a regulatory filing.

"In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand THE coverage to the rest of India," it added.

The drug manufactured by the company has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidised rate offered to government institutions, Dr Reddy's said.

"2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic," Dr Reddy's Chairman Satish Reddy said.